Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial - Garon, E B; Ciuleanu, T E; Arrieta, O (Lancet, 2014)
, et al.